Novel MFN2 compound heterozygote genotype in a patient with multiple symmetric lipomatosis and metabolic dysfunction
Journal of Clinical Lipidology · 2026-06 · 20 (6) · 1277-1282
DOI: 10.1016/j.jacl.2026.03.020 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Lipidology, 2026-06. Verfasst von Fabio Alexis Lefebvre und 2 weiteren Autor:innen. Beteiligte Einrichtung: Genetic Dyslipidemias Clinic, Montreal Clinical Research Institute, Montréal, Québec H2W 1R7, Canada (Lefebvre, Paquette, and Baass); Department of M…. Hauptthemen laut MEDLINE: Lipomatosis, Multiple Symmetrical, GTP Phosphohydrolases, Mitochondrial Proteins. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Inherited lipodystrophy syndromes are rare disorders of energy metabolism. Patients exhibit adipose tissue atrophy with metabolic dysregulation linked to ectopic fat deposition. Here, we describe the case of a 67-year-old woman presenting with partial adipose tissue atrophy, multiple symmetric lipomatosis, and muscle pseudohypertrophy. Metabolically, she had long-lasting diabetes mellitus with severe insulin resistance and hypertriglyceridemia. She developed hepatomegaly with steatosis, neuropathy, proteinuria, and coronary artery disease. In accordance with an inherited etiology, the patient's family history was positive for lipomatosis and premature heart disease. Targeted sequencing identified a variant in the MFN2 gene, previously linked to lipomatosis and Charcot-Marie-Tooth neuropathy. Copy number variation analysis revealed a novel 5.4 kb duplication in the MFN2 gene. Hence, we describe a novel compound heterozygote MFN2 genotype in this patient, which we believe accounts for her metabolic phenotype. Raising awareness of lipodystrophy syndromes is important because treatment with recombinant leptin, when available, can improve metabolic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genetic Dyslipidemias Clinic, Montreal Clinical Research Institute, Montréal, Québec H2W 1R7, Canada (Lefebvre, Paquette, and Baass); Department of Medicine, Division of Metabolic Medicine, UnIversité de Montréal, Montr…
- Genetic Dyslipidemias Clinic, Montreal Clinical Research Institute, Montréal, Québec H2W 1R7, Canada (Lefebvre, Paquette, and Baass).
- Genetic Dyslipidemias Clinic, Montreal Clinical Research Institute, Montréal, Québec H2W 1R7, Canada (Lefebvre, Paquette, and Baass); Department of Medicine, Divisions of Experimental Medicine and Medical Biochemistry,…
Zitieren
APA
Lefebvre, F. A., Paquette, M., & Baass, A. (2026). Novel MFN2 compound heterozygote genotype in a patient with multiple symmetric lipomatosis and metabolic dysfunction. Journal of Clinical Lipidology, 20(6), 1277-1282. https://doi.org/10.1016/j.jacl.2026.03.020
Vancouver
Lefebvre FA, Paquette M, Baass A. Novel MFN2 compound heterozygote genotype in a patient with multiple symmetric lipomatosis and metabolic dysfunction. Journal of Clinical Lipidology. 2026;20(6):1277-1282. doi:10.1016/j.jacl.2026.03.020
BibTeX
@article{Lefebvre2026,
author = {Lefebvre, Fabio Alexis and Paquette, Martine and Baass, Alexis},
title = {Novel MFN2 compound heterozygote genotype in a patient with multiple symmetric lipomatosis and metabolic dysfunction},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {6},
pages = {1277--1282},
doi = {10.1016/j.jacl.2026.03.020}
}
EUVIMED